Page 4 - Cipla Results

Cipla Q1 pre-tax profit jumps 20% to Rs 799 crore on strong revenues

Firm's domestic business did well, up 16% YoY during the quarter when Cipla launched licensed version of Gilead's remdesivir

US respiratory pipeline breathes in fresh optimism for Cipla; stock up 5%

Improving growth in North America will complement strong domestic sales

Cipla's profit before tax dips 35% to Rs 327.9 cr; India business grows 12%

The net profit came down 33 per cent to Rs 246 crore, lower than Street expectations. Emkay Global had expected a 3 per cent dip in profit for the quarter.

Domestic performance, steady growth outlook driving up Cipla stock

Promising domestic sales, new launches in the US are keeping analysts positive

Declining India business pulls down Cipla's Q1 growth; US sales grow

Profitability though got a boost with higher contribution from limited competition products in the US

Cipla posts Q4 net at Rs 1.53 bn on account of robust sales in key markets

Total income from operations stood at Rs 36.9797 billion. It was Rs 35.82 billion for the same period a year ago

Cipla poised to maintain high growth, earnings may grow by over 20%

Growth is expected to be strong in the March 2017-18 quarter (Q4) as well and in the current financial year

Cipla Q3 profit up 7% to Rs 4 bn, India revenue swells 15% to Rs 16 bn

Revenue from North America fell 2 percent due to ongoing pricing pressures in the generics market

Cipla's Q4 loss narrows to Rs 62 crore, scales down biotech business

Cipla its scaling down its biotech business after a weak fourth quarter which saw Rs 61.79 crore loss. In the same quarter last fiscal the company had posted Rs 93 crore loss.While the loss declined on a year on year basis the result was way below street estimates which was anticipating Rs 200-300 crore quarterly profit. Income from operations rose 8 per cent to Rs 3582 crore largely led by growth in the US market but sales slowed down in India and other emerging markets.Impairment charge of Rs 260 crore in relation to its biotech business and litigation for certain products in the US contributed to the loss."Operationally the quarter was in line with our guidance ," Cipla's chief executive officer Umang Vohra said. He added that the reported 14 per cent Ebidta margin included the one off impact of impairment and forex loss. Vohra said the company will not manufacture biosimilars and will outsource production of or look for inlicensing opportunities. The company has also put on ...

Cipla Q4 loss narrows to Rs 62 crore

Analysts on average had expected the firm would report a profit of Rs 345 crore